Amarin Corp Plc (AMRN)

[Pharmacydude]

Marjac
As I previously posted, estrogen is known to reduce ApoB and therefore the cropped ApoB table shows an expected reduction in ApoB levels in both the placebo (estrogen only) and the estrogen/EPA groups. Since it would be necessary to show that POSA at that time would know that, I have linked a study showing these results from 1997 just in case the generics argue that it wasn’t known at the time of the patent being issued.

Effect of Estrogen on Very Low Density Lipoprotein and Low Density Lipoprotein Subclass Metabolism in Postmenopausal Women

https://academic.oup.com/jcem/article/82/12/3955/2865931


“These metabolic changes reduced light LDL cholesterol and apoB concentrations by 26% (P = 0.005) and 19% (P = 0.03), respectively.”